Colombian health Minister Alejandro Gaviria is expected to formally request market regulators SIC to remove the exclusivity license granted to drug-makers Novartis for a legal monopoly on the sale of Gilvec Imatin B, a drug used to treat various kinds of cancer and leukemia. In doing so, the minister revives an old argument between Colombian health authorities and the Swiss multinational over its Intellectual Property rights.
Four years ago, an SIC resolution denied Novartis the exclusive patent on the chemical. However, the company appealed the decision before the State Council, which finally granted the exclusivity license in 2012.
“We were proposing to buy the supply at 140 pesos per milligram… Novartis Labs sent a communiqué to the Health and Social Protection Ministry, stating they refused to enter into negotiations and rejecting the proposal by the Ministry”. For this reason, Gaviria has asked the SIC to once again remove the exclusive license which currently bars Colombian labs to churn out generic versions of the product. The SIC has within its powers the ability to remove this license, stripping Novartis of its monopoly protection, by invoking a need for internal competition to lower consumer prices.
Full Content: El Colombiano
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI